Accelerating the Process of Drug Discovery
This introductory chapter is intended to provide a close examination of the role of drug metabolism and pharmacokinetics (DMPK) in accelerating the drug discovery process. In concentrating on this aspect, however, it is impossible to separate the role and importance of physical properties of the compounds under study. Whilst biological screening provides information of the effect of the compound on the biological system, DMPK data give a feedback of the effect of the biological system on the compound. The importance of physical properties in this will be highlighted. To do justice to this we have had to omit many other factors. Some of those which will not be discussed include the very important interaction of the discovery departments with other functions within pharmaceutical research and development (R&D). These include, for example, the input of the safety assessment function in an appropriate manner to ensure that early information is available to guide decision-making by discovery management.
KeywordsDrug Discovery Clearance Mechanism Metabolic Property Lead Optimisation Drug Discovery Process
Unable to display preview. Download preview PDF.
- Alper J (1994) Drug discovery on the assembly line. Science 264:1399–1401 Andersen Consulting Annual Report (1996) Approaches to improving drug discovery. Scrip 2278: 13Google Scholar
- Dorsey BD, McDaniel SL, Vacca JP, Guare JP, Darke PL, Zugay JA, Emini EA, Schlief WA (1994) L-735,524: The design of a potent and orally bioavailable HIV protease inhibitor J Med Chem 37: 3443–3451Google Scholar
- Drews J (1997) Cost of novel drug development. Scrip World Pharmaceutical News 2283: 8Google Scholar
- McAuslane N (1999) Accelerating preclinical development. Vision in Business, Conference 25–26 February, Nice, FranceGoogle Scholar
- Physician’s Desk Reference (1999) Medical Ergonomics Data Production Company, Montvale, NJ, USAGoogle Scholar
- Prentis RA, Lis Y, Walker SR (1988) Pharmaceutical innovation by the seven UK-owned pharmaceutical companies. Br J Clin Pharmacol 25:387–396 RD Insight ( 2001 ), Adis International Ltd, Chester, UKGoogle Scholar
- Rowland M, Tozer TN (1995) Clinical pharmacokinetics: concepts and applications, 3rd edn. Lippincott, Philadelphia, p 99Google Scholar
- Smith DA, van de Waterbeemd H (1999) Pharmacokinetics and metabolism inGoogle Scholar
- early drug discovery. Current Opinion in Chemical Biology 3:373–378 Teague SJ, Davis AM, Leeson PD, Oprea T (1999) The design of leadlike combinatorial libraries. Angew Chem Int Ed 38: 2743–2748Google Scholar
- Then RL (1993) History and future of antimicrobial diaminopyrimidines. J Chemother (Florence) 5: 361–368Google Scholar
- UK Office of Health Economics (1999) Scrip World Pharmaceutical News 2416: 27Google Scholar